Literature DB >> 19659788

Diagnostic value of a group of biochemical markers of liver fibrosis in patients with non-alcoholic steatohepatitis.

C Rinaldi A Lesmana1, Irsan Hasan, Unggul Budihusodo, Rino A Gani, Ening Krisnuhoni, Nurul Akbar, Laurentius A Lesmana.   

Abstract

OBJECTIVE: The objectives of this study were to investigate the use of non-invasive biochemical markers to evaluate the severity of liver fibrosis in patients with non-alcoholic steatohepatitis (NASH).
METHODS: This was a cross-sectional study of patients with histopathologically confirmed NASH between January 2005 and December 2006. The patients' characteristics were recorded and the body mass index was calculated for each patient. All patients underwent ultrasound-guided liver biopsy and a fibrosis assessment was performed using the Brunt criteria. The non-invasive laboratory markers measured were insulin resistance, tumor necrosis factor (TNF-alpha), type IV collagen and hyaluronic acid (HA).
RESULTS: Thirty patients were recruited, of whom 18 (60%) were men. Their mean age was 45 +/- 13.9 (18-71) years. About 83% of patients had fibrosis stage 1-2. In bivariate analysis, age, TNF-alpha and type IV collagen concentrations showed a weak but significant correlation with the fibrosis stage. When the patients were grouped into mild fibrosis (stages 1-2) and advanced fibrosis (stages 3-4), the mean concentrations of HA and type IV collagen were significantly higher in those with advanced fibrosis than those with mild fibrosis (180.8 +/- 49.63 vs 543.6 +/- 360.45 ng/mL; for HA; P = 0.026 and 125.3 +/- 32.11 vs 288.0 +/- 171.22 ng/mL for type IV collagen; P = 0.010).
CONCLUSION: Our study showed that the degree of liver fibrosis was significantly correlated with age, TNF-alpha and type IV collagen concentrations. The level of HA and type IV collagen could differentiate between mild (F1-2) and advanced fibrosis (F3-4).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19659788     DOI: 10.1111/j.1751-2980.2009.00386.x

Source DB:  PubMed          Journal:  J Dig Dis        ISSN: 1751-2972            Impact factor:   2.325


  24 in total

Review 1.  Role of cytokines and chemokines in non-alcoholic fatty liver disease.

Authors:  Vincent Braunersreuther; Giorgio Luciano Viviani; François Mach; Fabrizio Montecucco
Journal:  World J Gastroenterol       Date:  2012-02-28       Impact factor: 5.742

2.  Sevelamer Improves Steatohepatitis, Inhibits Liver and Intestinal Farnesoid X Receptor (FXR), and Reverses Innate Immune Dysregulation in a Mouse Model of Non-alcoholic Fatty Liver Disease.

Authors:  Brett M McGettigan; Rachel H McMahan; Yuhuan Luo; Xiaoxin X Wang; David J Orlicky; Cara Porsche; Moshe Levi; Hugo R Rosen
Journal:  J Biol Chem       Date:  2016-09-07       Impact factor: 5.157

3.  Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease.

Authors:  Anil Arora; Praveen Sharma
Journal:  J Clin Exp Hepatol       Date:  2012-07-21

4.  Liver volume and hepatic adiposity in childhood: relations to body growth and visceral fat.

Authors:  R Malpique; J Bassols; A López-Bermejo; M Diaz; F Villarroya; J Pavia; A Congo; F de Zegher; L Ibáñez
Journal:  Int J Obes (Lond)       Date:  2017-08-14       Impact factor: 5.095

5.  Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease.

Authors:  Veeral Ajmera; Emily R Perito; Nathan M Bass; Norah A Terrault; Katherine P Yates; Ryan Gill; Rohit Loomba; Anna Mae Diehl; Bradley E Aouizerat
Journal:  Hepatology       Date:  2016-10-12       Impact factor: 17.425

6.  The incretin enhancer, sitagliptin, exacerbates expression of hepatic inflammatory markers in rats fed a high-cholesterol diet.

Authors:  Rashmi Pathak; Avinash Kumar; Henry A Palfrey; Laura A Forney; Kirsten P Stone; Narayan R Raju; Thomas W Gettys; Subramanyam N Murthy
Journal:  Inflamm Res       Date:  2019-05-09       Impact factor: 4.575

Review 7.  CEACAM1 loss links inflammation to insulin resistance in obesity and non-alcoholic steatohepatitis (NASH).

Authors:  Sonia M Najjar; Lucia Russo
Journal:  Semin Immunopathol       Date:  2013-11-21       Impact factor: 9.623

8.  Intestinal mucosal barrier dysfunction participates in the progress of nonalcoholic fatty liver disease.

Authors:  Jing-Wei Mao; Hai-Ying Tang; Ting Zhao; Xiao-Yan Tan; Jian Bi; Bing-Yuan Wang; Ying-De Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

Review 9.  Nonalcoholic steatohepatitis and insulin resistance in children.

Authors:  Mikage Arata; Junya Nakajima; Shigeo Nishimata; Tomomi Nagata; Hisashi Kawashima
Journal:  World J Diabetes       Date:  2014-12-15

Review 10.  Genetics of non-alcoholic fatty liver disease: From susceptibility and nutrient interactions to management.

Authors:  Vishnubhotla Venkata Ravi Kanth; Mitnala Sasikala; Mithun Sharma; Padaki Nagaraja Rao; Duvvuru Nageshwar Reddy
Journal:  World J Hepatol       Date:  2016-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.